Drug intelligence / Profile preview

TeriQ

Development stage: Phase 1
Lead developer: Serán Bioscience
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Transdermal

Overview

TeriQ is an investigational drug product delivered as a dermal patch, currently being studied for its safety, tolerability, and pharmacokinetics in healthy adult female participants. The clinical trial compares the TeriQ Patch to Teribone Injection and Forteo Injection, both of which are established therapies for osteoporosis. The study uses escalating doses of the patch (28.2 μg, 56.5 μg, and 113.0 μg) to evaluate its effects relative to subcutaneous injections of comparator drugs[4][5]. While the precise active ingredient or mechanism is not explicitly stated in available sources, the context suggests that TeriQ may be related to parathyroid hormone analogs used in osteoporosis treatment.

Brand names: TeriQ Patch
Other names: TeriQ Patch

Beyond the preview

Go deeper on TeriQ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TeriQ.

Explore the full profile